Kite, a Gilead Company announced results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/II study evaluating its chimeric antigen receptor (CAR) T-cell therapy… read more.
What if we could prevent people from developing obesity? The World Obesity Federation expects more than half the global population to develop overweight or obesity by 2035. However,… read more.
Wearable healthcare devices, such as glucose monitors and heart monitors, are popular due to their ability to gather real-time data that supports users’ health and safety. However, despite… read more.
NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults. This is because the company did not provide… read more.
In an opinion piece published July 16 in the open-access journal PLOS Climate, Jeremy Jacobs of Vanderbilt University and Shazia Khan of Yale School of Medicine draw attention… read more.
Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type 2 diabetes, according to a new study being presented Monday at… read more.
NICE (UK): 1.1 Elafibranor is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in adults, when used: i) with ursodeoxycholic acid (UDCA), if… read more.
Researchers at the University of Pittsburgh have identified a new way of predicting whether a kidney donor and recipient are a good match for transplantation. The findings, published… read more.
Against the backdrop of high market demand for effective anti-ageing cosmetics, a team of Chinese researchers assessed the clinical effectiveness of a 0.1 % pterostilbene-containing skincare emulsion against a… read more.
Bayer announced that the FDA has accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for finerenone for the treatment of adult patients with heart… read more.
A new study that examined older and newer medications to treat seizures has found that using some medications during pregnancy is linked to an increased risk of malformations… read more.
Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered by Samsung… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
